Effect of Sertraline on Schizophrenia

Efficacy of Serteralin add-on therapy to Atypical Antipsychotics on maintenance therapy of schizophrenia patients on depression and level of function: Isfahan 2011-12

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201110187839N1

Enrollment

Registered

2011-11-13

Start date

2011-05-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia. The schizophrenic disorders are characterized in general by fundamental and characteristic distortions of thinking and perception, and affects that are inappropriate or blunted. Clear consciousness and intellectual capacity are usually maintained although

Interventions

Sertraline 50 mg/day was started for intervention group that could rise to 200mg/day gradually.In control group placbo pills that are identical to sertraline was prescribed.Both drug and placebo dail

Treatment - Drugs

Eligibility

Sex/Gender

All

Age

16 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:1-age:16-65y/o; 2-no substance abuse or sever medical disease; 3-no pregnancy or breast feeding; 4- patients medication should be one of atypical antipsychotics(Risperidone,Olanzapine,Aripiperazole,Quetiapine or Clozapine); 5- the patients are not in acute phase of disease; 6- the patients are on maintenance medication. Exclusion criteria:1-sever side effects; 2-no intrest in patient or his/her family to maintain on the study; 3-pregnancy; 4-drug non-tolerance.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Score of Depression. Timepoint: before starting study and after weeks 8,12. Method of measurement: CDSS(Calgray Depressive Scale of Schizophrenia).;Score of Quality of Life. Timepoint: before starting study and after weeks 8,12. Method of measurement: QLS questionare (Quality of life in Schizophrenia).;Score of Psychosis. Timepoint: before starting study and after weeks 8,12. Method of measurement: PANSS questionare (Positive And Negative Syndrome Scale).;Level of Function. Timepoint: before starting study and after weeks 8,12. Method of measurement: GAF questionare (Global Assessment of Function).	—

Measure

Time frame

Score of Depression. Timepoint: before starting study and after weeks 8,12. Method of measurement: CDSS(Calgray Depressive Scale of Schizophrenia).;Score of Quality of Life. Timepoint: before starting study and after weeks 8,12. Method of measurement: QLS questionare (Quality of life in Schizophrenia).;Score of Psychosis. Timepoint: before starting study and after weeks 8,12. Method of measurement: PANSS questionare (Positive And Negative Syndrome Scale).;Level of Function. Timepoint: before starting study and after weeks 8,12. Method of measurement: GAF questionare (Global Assessment of Function).

—

Secondary

Measure	Time frame
Side-effects of medication. Timepoint: weeks 8,12. Method of measurement: quastionare of side effects.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGhadir Mohammad Hoseiny

Isfahan University of Medical Sciences

ghadir-mhb@resident.mui.ac.ir drghadir@gmail.com+98 31 1447 8669

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026